Appointment of Andrew Lightfoot as Procarta CEO
Procarta has appointed Dr. Andrew Lightfoot as CEO to define and execute the strategy in bringing novel, proprietary antimicrobial agents to the clinic and to secure Series A funding. Dr Lightfoot commented "I am extremely passionate about antibiotic research and Procarta’s innovative platform technology has enormous potential to provide precision medicine antibiotics to multiple populations. Together we can drive this disruptive technology to clinical studies to test our hypothesis".
Dr Lightfoot, spent 12 years at GSK in drug discovery leadership roles in neuroscience and antibacterial research and in 2011 founded Peptinnovate, which has recently completed clinical studies in pursuing disease modifying agents derived from tuberculosis bacteria.